Clinical Trial Detail

NCT ID NCT03065062
Title Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

head and neck squamous cell carcinoma

pancreatic cancer

lung squamous cell carcinoma

endometrial cancer

Advanced Solid Tumor

Therapies

Gedatolisib + Palbociclib

Age Groups: senior adult

Additional content available in CKB BOOST